newsfilter
← Latest News
Business Wire·

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

  • Zura Bio Limited appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors effective February 21, 2026.
  • Neil Graham, M.B.B.S., M.D., M.P.H., stepped down from the Board on the same date to accept a full-time role limiting his service availability.
  • Mark Eisner currently serves as Executive Vice President & Chief Medical Officer at Vir Biotechnology after holding leadership roles at Sonoma Biotherapeutics, FibroGen, Genentech/Roche, & the University of California, San Francisco.
  • Ajay Nirula currently serves as Executive Vice President & Head of R&D at Recludix Pharma & previously led immunology at Eli Lilly & held roles at Amgen, Biogen Idec, & Merck & Co.
  • Dr. Nirula previously oversaw the development of Zura's lead candidate tibulizumab while at Eli Lilly & has served on Zura's Scientific Advisory Board.
  • Zura is a clinical-stage company developing dual-pathway antibodies & its lead candidate tibulizumab (ZB-106) is being evaluated in Phase 2 studies TibuSHIELD (hidradenitis suppurativa) & TibuSURE (systemic sclerosis).
  • Additional candidates crebankitug (ZB-168) & torudokimab (ZB-880) have completed Phase 1/1b studies & are being evaluated for various autoimmune & inflammatory conditions.